Source comparison
PT-141 Dosage Comparison: Clinical Trials vs Real-World Protocols
0.5–1.0 +0.10–0.15 (minimal) 8–10% Dose-sensitive individuals; initial titration phase Subtherapeutic for most users. Appropriate only for assessing individual tolerance before escalation 1.25–1.5 +0.20–0.25 (moderate) 12–15% Body weight <60kg; moderate respon
This comparison does not assign a generated winner or score.
- 0.5–1.0
- +0.10–0.15 (minimal)
- 8–10%
- Dose-sensitive individuals; initial titration phase
- Subtherapeutic for most users. Appropriate only for assessing individual tolerance before escalation
- 1.25–1.5
- +0.20–0.25 (moderate)
- 12–15%
- Body weight <60kg; moderate responders
- Effective maintenance dose for high-sensitivity melanocortin receptor variants. Underutilized clinically
- 1.75
- +0.30 (robust)
- 18–22%
- FDA-approved standard dose; moderate-to-high responders
- Optimal efficacy-to-tolerability ratio for 60–70% of users. Clinical trial gold standard
- 2.0–2.5
- +0.30–0.32 (no additional benefit)
- 35–40%
- Body weight >90kg; confirmed low responders only
- Minimal efficacy gain; disproportionate side effect increase. Reserve for documented non-responders at 1.75mg
- >2.5
- Data insufficient
- >45%
- Not recommended
- Exceeds known therapeutic ceiling. Adverse events outweigh any theoretical benefit